These properties are in good agreement with the observation that pharmacological and electroconvulsive AD treatments enhance activation of hippocampal post-synaptic 5-HT1A receptors (Haddjeri et al., 1998). The gene discussed is HTR1A; the disease is Alzheimer disease.